Maxim Group initiated coverage on Belite Bio with a new price target
$BLTE
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $60.00 | Buy | Maxim Group |
| 7/28/2023 | $43.00 | Overweight | Cantor Fitzgerald |
| 7/26/2023 | $25.00 | Outperform | SVB Securities |
| 8/1/2022 | $58.00 | Buy | H.C. Wainwright |
Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00
Cantor Fitzgerald initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $43.00
SVB Securities initiated coverage of Belite Bio with a rating of Outperform and set a new price target of $25.00
6-K - BELITE BIO, INC (0001889109) (Filer)
424B5 - BELITE BIO, INC (0001889109) (Filer)
6-K - BELITE BIO, INC (0001889109) (Filer)
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar
Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period)Enrollment completed with 529 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025Conference call and webcast on Monday, August 11, 2025, at 4:30 p.m. ET SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares ("ADSs") and warrants to purchase 230,770 ADSs, at a purchase price of $65 per ADS and accompanying warrant, pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $1
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation11:00 am ET, "Pivotal-Stage Assets for Retinal Disorders" panel discussion Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events"
SC 13G - BELITE BIO, INC (0001889109) (Subject)
SC 13G - BELITE BIO, INC (0001889109) (Subject)
SC 13G - BELITE BIO, INC (0001889109) (Subject)
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,
Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET
In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease ("STGD1") trial ("LBS-008-CT02"), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjectsA continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal lesions was reduced with Tinlarebant in LBS-008-CT02 compared to a natural history study of the disease ("ProgStar")Stabilization of visual acuity with no significant loss and no clinically significant changes in retinal thickness observed over 18 months of treatment with Tinlarebant in LBS-008-CT0258 subjects have been enrolled in the pivotal Phase 3 "DRAGON" trial eva